Genomic Vision Announces a Strategic Partnership With GIPTIS (Genetics Institute for Patients, Therapies, Innovation & Scienc...
15 Gennaio 2020 - 07:30AM
Business Wire
- Genomic Vision rallied behind GIPTIS to fight against rare
diseases, a major public health issue
- Several research programs, using Genomic Vision technology
and equipment, will be launched in this unique center to speed up
the development of treatments
- New assays will be commercialized by Genomic Vision, under
GIPTIS approval and guidance
Regulatory News:
GENOMIC VISION (Paris:GV) (FR0011799907 – GV), a
biotechnology company developing Molecular and Artificial
Intelligence tools to investigate DNA structural and dynamic
changes, in particular in the human genome, is pleased to announce
a partnership with GIPTIS, the future Euro Mediterranean Institute
founded by Professor Nicolas Lévy, head of the Medical Genetic
Department at the renowned hospital of “La Timone” in Marseille.
The aim of this partnership is to accelerate and facilitate the
diagnosis and treatment of patients, thanks to Genomic Vision
proprietary technology and expertise.
In order to improve the management of patients affected by rare
genetic diseases, GIPTIS has defined as main objectives to
accelerate diagnosis, increase research capacity, multiply the
number of effective treatments and improve the care of patients and
families.
Professor Nicolas Lévy explains: “Genomic Vision has
developed a powerful technology that helps to understand complex
genetic abnormalities, in particular in aging and neurological
diseases, two therapeutic areas with high unmet clinical needs. It
is really helpful in particular to characterize genomic regions
with highly repeated sequences for which NGS technologies are not
efficient enough.”
Terms of the partnership include several research programs with
the development of news assays targeting specific genetic disorders
on which Genomic Vision will have exclusive commercialization
rights.
Aaron Bensimon, CEO and co-founder of Genomic Vision,
adds: “It is the fusion between technological innovation and
unmet clinical needs that will cross the frontiers and will bring
to the doctors and patients novel tests. Genomic Vision and GIPTIS
are the appropriate partners to develop such a novel approach.
GIPTIS will bring to GV an important source of unmet medical need
in the field of neurological diseases and will be a major asset for
the development and validation of these new tests. We are very
proud to have been selected by this prestigious institute to
participate in this outstanding project. It is not only an
opportunity to set-up new IVD assays, but also an opening to
Southern markets in which genetic disease rates are higher than
elsewhere.”
ABOUT GIPTIS
Today, rare genetic diseases affect 3 million people in France,
more than cancer and Alzheimer's disease combined, and 50 million
around the Mediterranean. More than 95% of patients are without
adequate treatment and 60% of them are children.
In the majority of cases, these diseases are serious, disabling,
chronic and have an impact on entire families.
The aim of GIPTIS: to treat patients better, faster and on a
larger scale by facilitating collaborations between the best of the
public and private sectors, academic and industrial worlds. GIPTIS
unites medical teams, fundamental and applied research teams,
start-ups, drug companies and patients associations in the same
innovative place of excellence.
GIPTIS faces 4 challenges: accelerate the diagnoses, increase
research capacity, multiply the number of effective treatments,
improve care for patients and families.
Founded by internationally acclaimed geneticist, Professor
Nicolas Lévy, GIPTIS will be a non-profit foundation with mixed
governance, for successful cooperation between private and public
sectors.
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company developing molecular
assays and Artificial Intelligence tools to control quality and
safety of genetically modified genomes, in particular in genome
editing technologies and biomanufacturing processes. These tools
are currently use for monitoring DNA replication in cancerous cell,
for early cancer detection and the diagnosis of genetic diseases.
Based near Paris, in Bagneux, the Company has approximately 30
employees. GENOMIC VISION is a public listed company listed in
compartment C of Euronext’s regulated market in Paris (Euronext: GV
– ISIN: FR0011799907).
For further information, please visit www.genomicvision.com.
Membre des indices CAC® Mid & Small et CAC®
All-Tradable
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the reference
document dated March 29, 2019 filed with the AMF under reference
number R19-004, available on the web site of Genomic Vision
(www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200114005771/en/
Genomic Vision Aaron Bensimon Co-founder, Chairman &
CEO +33 1 49 08 07 50 investisseurs@genomicvision.com
Ulysse Communication Press Relations Bruno Arabian
+33 1 42 68 29 70 barabian@ulysse-communication.com
NewCap Investor Relations & Strategic
Communications +33 1 44 71 94 94 gv@newcap.eu
Grafico Azioni Genomic Vision (EU:GV)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Genomic Vision (EU:GV)
Storico
Da Mar 2023 a Mar 2024